Company intelligence / Profile preview

Bellwether Bio

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Proof-of-concept published demonstrating cell-free DNA nucleosome positioning as a tissue-of-origin diagnostic, acquired to enhance Guardant Health's early stage cancer detection pipeline; sensitivity improvements shown for early-stage colorectal cancer when integrated into liquid biopsy assays[1][6].

Therapeutic areas: OncologyOther
Modalities: Diagnostic technology
Industry: Molecular Diagnostics

Partnerships

Guardant Health (acquirer)University of Washington (spinout)Collaborations with cancer diagnostics companies (undisclosed)

Beyond the preview

Go deeper on Bellwether Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bellwether Bio.

Explore the full profile